1 Papers
137 Citations
David Ashton is an academic researcher from Johnson & Johnson Pharmaceutical Research and Development. The author has contributed to research in topics: Receptor & Elevated plus maze. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
Anxiolytic- and antidepressant-like profile of a new CRF1 receptor antagonist, R278995/CRA0450.
Shigeyuki Chaki,Atsuro Nakazato,Ludo Edmond Josephine Kennis,Masato Nakamura,Claire Mackie,Masayuki Sugiura,Petra Vinken,David Ashton,Xavier Langlois,Thomas Steckler +9 more
TL;DR: Results indicate that R278995/CRA0450 is an orally active CRF (1) and sigma(1) receptor antagonist with potent anxiolytic-like and antidepressant-like activities.
142